These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
514 related articles for article (PubMed ID: 33724296)
1. Short-course radiotherapy with consolidation chemotherapy versus conventionally fractionated long-course chemoradiotherapy for locally advanced rectal cancer: randomized clinical trial. Chakrabarti D; Rajan S; Akhtar N; Qayoom S; Gupta S; Verma M; Srivastava K; Kumar V; Bhatt MLB; Gupta R Br J Surg; 2021 May; 108(5):511-520. PubMed ID: 33724296 [TBL] [Abstract][Full Text] [Related]
2. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP; Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740 [TBL] [Abstract][Full Text] [Related]
3. Clinical Analysis of the Efficacy and Safety of Different Neoadjuvant Strategies in the Treatment of Locally Advanced Rectal Cancer. Chen W; Wang W; Huang S; Zhou L; Wang G; Chen W Cancer Invest; 2024 Aug; 42(7):661-670. PubMed ID: 39037150 [TBL] [Abstract][Full Text] [Related]
4. Randomized Controlled Trial of Neoadjuvant Short-Course Radiotherapy Followed by Consolidation Chemotherapy Versus Long-Course Chemoradiotherapy in Locally Advanced Rectal Cancer: Comparison of Overall Response Rates. Amariyil A; Pathy S; Sharma A; Kumar S; Pramanik R; Bhoriwal S; Pandey RM J Gastrointest Cancer; 2024 Mar; 55(1):373-382. PubMed ID: 37702850 [TBL] [Abstract][Full Text] [Related]
5. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE). Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356 [TBL] [Abstract][Full Text] [Related]
6. A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03. Kim SY; Joo J; Kim TW; Hong YS; Kim JE; Hwang IG; Kim BG; Lee KW; Kim JW; Oh HS; Ahn JB; Zang DY; Kim DY; Oh JH; Baek JY Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):889-899. PubMed ID: 29976501 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. Dellas K; Höhler T; Reese T; Würschmidt F; Engel E; Rödel C; Wagner W; Richter M; Arnold D; Dunst J Radiat Oncol; 2013 Apr; 8():90. PubMed ID: 23587311 [TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T; Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067 [TBL] [Abstract][Full Text] [Related]
9. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study. Zhu J; Liu F; Gu W; Lian P; Sheng W; Xu J; Cai G; Shi D; Cai S; Zhang Z Radiat Oncol; 2014 Mar; 9():70. PubMed ID: 24606870 [TBL] [Abstract][Full Text] [Related]
10. Total neoadjuvant therapy with short-course radiotherapy Versus long-course neoadjuvant chemoradiotherapy in Locally Advanced Rectal cancer, Korean trial (TV-LARK trial): study protocol of a multicentre randomized controlled trial. Kim MJ; Lee DW; Kang HC; Park JW; Ryoo SB; Han SW; Kim KS; Chie EK; Oh JH; Jeong WK; Kim BH; Nam EM; Jeong SY BMC Cancer; 2023 Aug; 23(1):734. PubMed ID: 37553666 [TBL] [Abstract][Full Text] [Related]
11. The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)-cT3 rectal cancer. Valentini V; Gambacorta MA; Cellini F; Aristei C; Coco C; Barbaro B; Alfieri S; D'Ugo D; Persiani R; Deodato F; Crucitti A; Lupattelli M; Mantello G; Navarria F; Belluco C; Buonadonna A; Boso C; Lonardi S; Caravatta L; Barba MC; Vecchio FM; Maranzano E; Genovesi D; Doglietto GB; Morganti AG; La Torre G; Pucciarelli S; De Paoli A Radiother Oncol; 2019 May; 134():110-118. PubMed ID: 31005204 [TBL] [Abstract][Full Text] [Related]
12. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors]. Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549 [No Abstract] [Full Text] [Related]
13. Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002). Wang J; Guan Y; Gu W; Yan S; Zhou J; Huang D; Tong T; Li C; Cai S; Zhang Z; Zhu J Radiat Oncol; 2019 Nov; 14(1):215. PubMed ID: 31783766 [TBL] [Abstract][Full Text] [Related]
14. Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma. Jia AY; Narang A; Safar B; Zaheer A; Murphy A; Azad NS; Gearhart S; Fang S; Efron J; Warczynski T; Hacker-Prietz A; Meyer J Radiat Oncol; 2019 Aug; 14(1):147. PubMed ID: 31426827 [TBL] [Abstract][Full Text] [Related]
15. [Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre, randomized phase II trial (TORCH)]. Wang YQ; Shen LJ; Wan JF; Zhang H; Wang Y; Wu X; Wang JW; Wang RJ; Sun YQ; Tong T; Huang D; Wang L; Sheng WQ; Zhang X; Cai GX; Xu Y; Cai SJ; Zhang Z; Xia F Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):448-458. PubMed ID: 37217353 [No Abstract] [Full Text] [Related]
16. Neoadjuvant-intensified treatment for rectal cancer: time to change? Musio D; De Felice F; Bulzonetti N; Guarnaccia R; Caiazzo R; Bangrazi C; Raffetto N; Tombolini V World J Gastroenterol; 2013 May; 19(20):3052-61. PubMed ID: 23716984 [TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II). PelvEx Collaborative BJS Open; 2021 May; 5(3):. PubMed ID: 34089596 [TBL] [Abstract][Full Text] [Related]
18. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J; BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495 [TBL] [Abstract][Full Text] [Related]
19. Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial). Akiyoshi T; Shinozaki E; Taguchi S; Chino A; Hiratsuka M; Tominaga T; Nonaka T; Toda S; Matoba S; Matsui S; Okabayashi K; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Yamaguchi K; Ueno M; Kuroyanagi H; Fukunaga Y; Ishizuka N; Konishi T; BMJ Open; 2022 Mar; 12(3):e055140. PubMed ID: 35304396 [TBL] [Abstract][Full Text] [Related]
20. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors]. Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301 [No Abstract] [Full Text] [Related] [Next] [New Search]